Ovid Therapeutics Inc (OVID)

NASDAQ
Currency in USD
Disclaimer
3.230
-0.100(-3.00%)
Closed
After Hours
3.2300.000(0.00%)
Day's Range
3.2303.350
52 wk Range
1.6204.139
Prev. Close
3.33
Open
3.31
Day's Range
3.23-3.35
52 wk Range
1.62-4.139
Volume
63,405
Average Vol. (3m)
116,487
1-Year Change
79.44%
Shares Outstanding
70,680,551
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
6.000
Upside +85.759%

People Also Watch

83.74
TTC
-0.83%
194.78
APPF
+0.81%
9.70
SNBR
-6.69%
183.95
AZPN
-1.06%
180.96
EXP
+0.91%
How do you feel today about OVID?
Vote to see community's results!
or

Ovid Therapeutics Inc Company Profile

Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing medicines for patients and families living with epilepsies and seizure-related neurological disorders. The Company is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. The Company’s genetic research programs include OV815 and OV825 and OV882. OV815 focuses on the mutations associated with KIF1A-associated neurological disorder (KAND). OV825 has advanced to candidate lead identification for the rare neurodevelopmental condition HNRNPH2. OV882 is a short hairpin RNA that the Company is evaluating as a potential disease-modifying gene therapy for Angelman syndrome. OV329 is an investigational, next-generation GABA-AT inhibitor that the Company is developing for the treatment of adult and pediatric epilepsy disorders.